(Q34210759)

31 July 2017

title

II. In vitro evidence that (-)-OSU6162 and (+)-OSU6162 produce their behavioral effects through 5-HT2A serotonin and D2 dopamine receptors (English)

1 reference

31 July 2017

Ethan S Burstein

1

1 reference

31 July 2017

Maria L Carlsson

2

1 reference

31 July 2017

Michelle Owens

3

1 reference

31 July 2017

Jian-Nong Ma

4

1 reference

31 July 2017

Hans H Schiffer

5

1 reference

31 July 2017

Arvid Carlsson

6

1 reference

31 July 2017

Uli Hacksell

7

1 reference

31 July 2017

publication date

25 August 2011

1 reference

Journal of Neural Transmission

31 July 2017

published in

1 reference

31 July 2017

volume

118

1 reference

31 July 2017

issue

11

1 reference

31 July 2017

page(s)

1523-1533

1 reference

Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0701-Y

Integrative functional assays, chemical genomics and high throughput screening: harnessing signal transduction pathways to a common HTS readout

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0701-Y

Characterization of the Mas-related gene family: structural and functional conservation of human and rhesus MrgX receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0701-Y

Identification and characterization of novel small-molecule protease-activated receptor 2 agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0701-Y

Analysis of the actions of the novel dopamine receptor-directed compounds (S)-OSU6162 and ACR16 at the D2 dopamine receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0701-Y

Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine(preclamol) in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0701-Y

Stimulating and inhibitory effects of the dopamine "stabilizer" (-)-OSU6162 on dopamine D2 receptor function in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0701-Y

Identification of the atypical L-type Ca2+ channel blocker diltiazem and its metabolites as ghrelin receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0701-Y

Characterization of highly efficacious allosteric agonists of the human calcium-sensing receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0701-Y

Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0701-Y

The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for mot

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0701-Y

Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0701-Y

Effects of (-)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0701-Y

Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0701-Y

Discovery of an ectopic activation site on the M(1) muscarinic receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0701-Y

Long-lasting improvement following (-)-OSU6162 in a patient with Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0701-Y

G-protein-coupled receptor-mediated activation of rap GTPases: characterization of a novel Galphai regulated pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-011-0701-Y

I. In vivo evidence for partial agonist effects of (-)-OSU6162 and (+)-OSU6162 on 5-HT2A serotonin receptors

21 January 2018

1 reference

12 December 2020

5-hydroxytryptamine2A receptor inverse agonists as antipsychotics

1 reference

12 December 2020

Terguride in parkinsonism. A multicenter trial

1 reference

12 December 2020

An evaluation of the partial dopamine agonist terguride regarding positive symptoms reduction in schizophrenics

1 reference

12 December 2020

Partial agonists in schizophrenia--why some work and others do not: insights from preclinical animal models

1 reference

12 December 2020

10.1007/S00702-011-0701-Y

Identifiers

DOI

1 reference

31 July 2017

1 reference